US equities |
SPCX $167.75 ▲+5.53% NVDA $236.62 ▲+1.14% MU $1,067.07 ▼-0.73% TSLA $378.57 ▲+2.15% MSFT $526.20 ▲+1.68% SNDK $1,710.65 ▼-0.54% INTC $117.08 ▼-1.89% META $745.00 ▲+2.32%
FinancialContent

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.74 -0.09 (-0.57%)
Delayed Quote Updated: 12:58 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Aurinia Settles Patent Litigation with Teva
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum Rating ↗
Via Chartmill
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Screens Strong on Minervini Trend Template and High Growth Momentum ↗
Via Chartmill
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH): A High-Growth Momentum and Technical Trend Case Study ↗
Via Chartmill
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Key Growth Screener from "The Little Book That Makes You Rich" ↗
Via Chartmill
Aurinia Pharmaceuticals (NASDAQ:AUPH) Beats Q4 2025 Estimates and Provides 2026 Guidance ↗
Via Chartmill
News headline image
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million ↗
This biopharma firm, focused on therapies for autoimmune diseases, reported a recent insider buy amid a year of strong share performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ:... 
Via Newsfile
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery ↗
Via Stocktwits
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Announces Management Transition
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates ↗
Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data. 
Via Stocktwits
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next. 
Via The Motley Fool
News headline image
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Passes Louis Navellier's Strict Growth Stock Screen ↗
Aurinia Pharmaceuticals (AUPH) exemplifies a top growth stock, showing explosive earnings growth, soaring cash flow, and consistent earnings surprises. 
Via Chartmill
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
A Peek at Aurinia Pharmaceuticals's Future Earnings ↗
 
Via Benzinga
News headline image
FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse ↗
FDA drug center head George Tidmarsh resigned after accusations of misusing power to harm a former business associate. He denies wrongdoing. 
Via Benzinga
News headline image
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ ↗
Things got murkier at the FDA’s drug evaluation agency as its acting director stepped down, alleging that a new drug approval program injected politics, superseding decisions based on science. 
Via Stocktwits
Topics Lawsuit
News headline image
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Traits in Fundamental Analysis ↗
Discover Aurinia Pharmaceuticals (AUPH), a top growth stock with explosive earnings, soaring revenue, and high ROE, using Louis Navellier's proven investment strategy. 
Via Chartmill
News headline image
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Responds to Now Retracted LinkedIn Post
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >